The Trump administration released new dietary guidelines on Wednesday, pushing Americans to prioritize protein and cut back ...
“Today marks a decisive change in federal nutrition policy,” the health secretary, Robert F. Kennedy Jr., said at a briefing ...
Obesity and diabetes treatment is undergoing a revolution with the advent of GLP-1 drugs, which help manage weight, control ...
Novo Nordisk A/S launches oral Wegovy in the U.S. with aggressive pricing as China patent expiry looms. Click for this ...
Zacks Investment Research on MSN
LLY up 28% in 3 months: Is it the right time to invest in the stock?
Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, ...
Zacks Investment Research on MSN
Here's how VKTX's obesity drug is moving quickly through phase III
Viking Therapeutics VKTX is one of the few companies with a late-stage obesity candidate in its pipeline. The company is ...
The American Diabetes Association® (ADA) welcomes the 2026 principal officers and board of directors. The 15-member board comprises forward-thinking and innovative medical, scientific, education, and ...
Diabetes mellitus could drain tens of trillions from the global economy, with informal caregiving emerging as the largest ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Clinical trials underrepresent women, children, and adults aged 65 years or older, so diabetes guidelines must be adapted to ...
Withings sells smart scales, smart watches, blood pressure monitors, and other health-tracking devices, including a recently announced urine sensor. Users can begin tracking their glucose levels ...
Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback